2020年12月2日 · The Non-Target Subset (n = 133) failed to show any clinically significant ETT response to rintatolimod when compared to placebo. Within the Target Subset, 51.2% of rintatolimod-treated patients improved their exercise duration by ≥25% (p = 0.003) despite reduced statistical power from division of the original ITT population into two subsets.

2016年4月7日 · Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/ myalgic encephalomyelitis (cfs/me). Mitchell WM1. Author information 1a Department of Pathology, Microbiology & Immunology , Vanderbilt University. Expert Rev Clin Pharmacol. 2016 Apr 5. [Epub ahead of print] Abstract...

Welcome to Phoenix Rising! Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

2020年12月2日 · There was one patient on this forum who started taking Abilify in 2012; you may be able to contact them and ask.

2015年8月10日 · Search titles only By: Search Advanced search…

2018年10月23日 · ORLANDO, Fla., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today regulatory inspection and clearance for distribution of the Company's second commercial scale lot of Ampligen® (rintatolimod), which is slated for multiple uses including product launch in Argentina, where Ampligen is approved for ...

2010年11月8日 · Welcome to Phoenix Rising! Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

2020年6月25日 · Ampligen (rintatolimod) is an interferon inducer which stimulates the immune system to fight viral infections. Ampligen has been shown efficacious for ME/CFS in a phase III clinical trial. Ampligen is licensed as an ME/CFS treatment in Argentina, but not in the US or Europe, so is difficult to obtain, and not normally covered by insurance.

2021年5月16日 · Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for ME/CFS ...

2015年6月16日 · Conclusion: Trials of rintatolimod, counseling therapies, and graded exercise therapy suggest benefit for some patients meeting case definitions for CFS, whereas evidence for other treatments and harms is insufficient. More definitive studies comparing participants meeting different case definitions, including ME, and providing subgroup ...